Anti-Α-Galactosidase: Anti-Body Riposte to Agalsidase Beta Growth in Fabry Disease Patients

Muhammad Naveed Ahmad, Zeeshan Nasir, Daniyal Qayyum


Fabry disease is a X-connected lysosomal stockpiling issue caused by an inadequacy in α-galactosidase A (α-lady A). Catalyst substitution treatment (ERT) comprises of general mixtures of recombinant α-lady A. Fabry sickness patients usually create IgG antibodies against this catalyst and there is a worry that they may decrease the viability and security of ERT. We built up an ELISA to quantify hostile to α-lady An IgG antibodies and found that 61% of patients on ERT were seropositive. We likewise composed a quick, single-chromatography cleaning convention for α-lady A from the supernatant of a human embryonic kidney 293T cell line built to steadily overexpress a 6xhis-labeled human α-lady A. We got 0.342 mg/L with the normal sub-atomic weight yet bring down enzymatic action than anticipated. This α-lady An is bound by antibodies from seropositive patients and not by those from solid people, which recommends that it might fill in as antigen in our ELISA to quantify against α-lady An antibodies.


anti-α-galactosidase, antibody, agalsidase beta development, fabry disease patients

Full Text:



Abe, Akira, Lois J. Arend, Lihsueh Lee, Clifford Lingwood, Roscoe O. Brady, and James A. Shayman. 2000. “Glycosphingolipid Depletion in Fabry Disease Lymphoblasts with Potent Inhibitors of Glucosylceramide Synthase.” Kidney International 57 (2): 446–54. doi:10.1046/j.1523-1755.2000.00864.x.

Abe, Akira, Susan Gregory, Lihsueh Lee, Paul D. Killen, Roscoe O. Brady, Ashok Kulkarni, and James A. Shayman. 2000. “Reduction of Globotriaosylceramide in Fabry Disease Mice by Substrate Deprivation.” Journal of Clinical Investigation 105 (11): 1563–71. doi:10.1172/JCI9711.

Aerts, Johannes M., Johanna E. Groener, Sijmen Kuiper, Wilma E. Donker-Koopman, Anneke Strijland, Roelof Ottenhoff, Cindy van Roomen, et al. 2008. “Elevated Globotriaosylsphingosine Is a Hallmark of Fabry Disease.” Proceedings of the National Academy of Sciences of the United States of America 105 (8): 2812–17. doi:10.1073/pnas.0712309105.

Aguilar, R. C., M. Boehm, I. Gorshkova, R. J. Crouch, K. Tomita, T. Saito, H. Ohno, and J. S. Bonifacino. 2001. “Signal-Binding Specificity of the mu4 Subunit of the Adaptor Protein Complex AP-4.” The Journal of Biological Chemistry 276 (16): 13145–52. doi:10.1074/jbc.M010591200.

Akiyama, Masashi, Yoriko Sugiyama-Nakagiri, Kaori Sakai, James R. McMillan, Maki Goto, Ken Arita, Yukiko Tsuji-Abe, et al. 2005. “Mutations in Lipid Transporter ABCA12 in Harlequin Ichthyosis and Functional Recovery by Corrective Gene Transfer.” The Journal of Clinical Investigation 115 (7): 1777–84. doi:10.1172/JCI24834.

Allen, L. E., E. M. Cosgrave, J. P. Kersey, and U. Ramaswami. 2010. “Fabry Disease in Children: Correlation between Ocular Manifestations, Genotype and Systemic Clinical Severity.” The British Journal of Ophthalmology 94 (12): 1602–5. doi:10.1136/bjo.2009.176651.

Altarescu, Gheona, David F. Moore, and Raphael Schiffmann. 2005. “Effect of Genetic Modifiers on Cerebral Lesions in Fabry Disease.” Neurology 64 (12): 2148–50. doi:10.1212/01.WNL.0000166000.24321.4F.

Apelland, Turid, Einar Gude, Erik H. Strøm, Lars Gullestad, Kristin L. Eiklid, Jan-Eric Månsson, Finn P. Reinholt, et al. 2014. “Familial Globotriaosylceramide-Associated Cardiomyopathy Mimicking Fabry Disease.” Heart (British Cardiac Society) 100 (22): 1793–98. doi:10.1136/heartjnl-2014-305616.

Arab, S., and C. A. Lingwood. 1998. “Intracellular Targeting of the Endoplasmic Reticulum/nuclear Envelope by Retrograde Transport May Determine Cell Hypersensitivity to Verotoxin via Globotriaosyl Ceramide Fatty Acid Isoform Traffic.” Journal of Cellular Physiology 177 (4): 646–60. doi:10.1002/(SICI)1097-4652(199812)177:4<646::AID- JCP15>3.0.CO;2-B.

Arai, T., A. K. Bhunia, S. Chatterjee, and G. B. Bulkley. 1998. “Lactosylceramide Stimulates Human Neutrophils to Upregulate Mac-1, Adhere to Endothelium, and Generate Reactive Oxygen Metabolites in Vitro.” Circulation Research 82 (5): 540–47.

Bénichou, Bernard, Sunita Goyal, Crystal Sung, Andrea M. Norfleet, and Fanny O’Brien. 2009. “A Retrospective Analysis of the Potential Impact of IgG Antibodies to Agalsidase Beta on Efficacy during Enzyme Replacement Therapy for Fabry Disease.” Molecular Genetics and Metabolism 96 (1): 4–12. doi:10.1016/j.ymgme.2008.10.004.

Beutler, E., and W. Kuhl. 1972. “Purification and Properties of Human Alpha-Galactosidases.” The Journal of Biological Chemistry 247 (22): 7195–7200.

Bhat, S., R. V. Mettus, E. P. Reddy, K. E. Ugen, V. Srikanthan, W. V. Williams, and D. B. Weiner. 1993. “The Galactosyl Ceramide/sulfatide Receptor Binding Region of HIV-1 gp120 Maps to Amino Acids 206-275.” AIDS Research and Human Retroviruses 9 (2): 175–81. doi:10.1089/aid.1993.9.175.

Bhunia, A. K., T. Arai, G. Bulkley, and S. Chatterjee. 1998. “Lactosylceramide Mediates Tumor Necrosis Factor-Alpha-Induced Intercellular Adhesion Molecule-1 (ICAM-1) Expression and the Adhesion of Neutrophil in Human Umbilical Vein Endothelial Cells.” The Journal of Biological Chemistry 273 (51): 34349–57.

Cook, D. G., J. Fantini, S. L. Spitalnik, and F. Gonzalez-Scarano. 1994. “Binding of Human Immunodeficiency Virus Type I (HIV-1) gp120 to Galactosylceramide (GalCer): Relationship to the V3 Loop.” Virology 201 (2): 206–14. doi:10.1006/viro.1994.1287.

Corchero, José Luis, Rosa Mendoza, Julia Lorenzo, Victor Rodríguez-Sureda, Carmen Domínguez, Esther Vázquez, Neus Ferrer-Miralles, and Antonio Villaverde. 2011. “Integrated Approach to Produce a Recombinant, His-Tagged Human α-Galactosidase a in Mammalian Cells.” Biotechnology Progress 27 (5): 1206–17. doi:10.1002/btpr.637.

Donati, D., R. Novario, and L. Gastaldi. 1987. “Natural History and Treatment of Uremia Secondary to Fabry’s Disease: An European Experience.” Nephron 46 (4): 353–59.

Doray, Balraj, Kerry Bruns, Pradipta Ghosh, and Stuart Kornfeld. 2002. “Interaction of the Cation- Dependent Mannose 6-Phosphate Receptor with GGA Proteins.” The Journal of Biological Chemistry 277 (21): 18477–82. doi:10.1074/jbc.M201879200.

Ferrans, V. J., R. G. Hibbs, and C. D. Burda. 1969. “The Heart in Fabry’s Disease. A Histochemical and Electron Microscopic Study.” The American Journal of Cardiology 24 (1): 95–110.

Font, R. L., and B. S. Fine. 1972. “Ocular Pathology in Fabry’s Disease. Histochemical and Electron Microscopic Observations.” American Journal of Ophthalmology 73 (3): 419–30.

Forstner, G. G., K. Tanaka, and K. J. Isselbacher. 1968. “Lipid Composition of the Isolated Rat Intestinal Microvillus Membrane.” The Biochemical Journal 109 (1): 51–59.

Gothot, A, J C van der Loo, D W Clapp, and E F Srour. 1998. “Cell Cycle-Related Changes in Repopulating Capacity of Human Mobilized Peripheral Blood CD34(+) Cells in Non-Obese Diabetic/severe Combined Immune-Deficient Mice.” Blood 92 (8): 2641–49.

Gribben, J. G., S. Devereux, N. S. B. Thomas, M. Keim, H. M. Jones, A. H. Goldstone, and D. C. Linch. 1990. “Development of Antibodies to Unprotected Glycosylation Sites on Recombinant Human GM-CSF.” The Lancet 335 (8687): 434–37. doi:10.1016/0140- 6736(90)90665-R.

Grunnet, M. L., and P. R. Spilsbury. 1973. “The Central Nervous System in Fabry’s Disease. An Ultrastructural Study.” Archives of Neurology 28 (4): 231–34.

Guan, Feng, Kazuko Handa, and Sen-itiroh Hakomori. 2009. “Specific Glycosphingolipids Mediate Epithelial-to-Mesenchymal Transition of Human and Mouse Epithelial Cell Lines.” Proceedings of the National Academy of Sciences of the United States of America 106 (18): 7461–66. doi:10.1073/pnas.0902368106.

Hammache, D., N. Yahi, G. Piéroni, F. Ariasi, C. Tamalet, and J. Fantini. 1998. “Sequential Interaction of CD4 and HIV-1 gp120 with a Reconstituted Membrane Patch of Ganglioside GM3: Implications for the Role of Glycolipids as Potential HIV-1 Fusion Cofactors.” Biochemical and Biophysical Research Communications 246 (1): 117–22. doi:10.1006/bbrc.1998.8531.

Hanada, Kentaro, Keigo Kumagai, Satoshi Yasuda, Yukiko Miura, Miyuki Kawano, Masayoshi Fukasawa, and Masahiro Nishijima. 2003. “Molecular Machinery for Non-Vesicular Trafficking of Ceramide.” Nature 426 (6968): 803–9. doi:10.1038/nature02188.

Hoffmann, Bjoern, Martin Schwarz, Atul Mehta, and Satish Keshav. 2007. “Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement Therapy.” Clinical Gastroenterology and Hepatology 5 (12): 1447–53. doi:10.1016/j.cgh.2007.08.012.

Holleran, Walter M., Edward I. Ginns, Gopinathan K. Menon, Jens Uwe Grundmann, Manigé Fartasch, Cindy E. McKinney, Peter M. Elias, and Ellen Sidransky. 1994. “Consequences of β-Glucocerebrosidase Deficiency in Epidermis: Ultrastructure and Permeability Barrier Alterations in Gaucher Disease.” Journal of Clinical Investigation 93 (4): 1756–64. doi:10.1172/JCI117160.

Keilmann, A., D. Hajioff, U. Ramaswami, and FOS Investigators. 2009. “Ear Symptoms in Children with Fabry Disease: Data from the Fabry Outcome Survey.” Journal of Inherited Metabolic Disease 32 (6): 739–44. doi:10.1007/s10545-009-1290-x.

Keith, D. H., J. Singer-Sam, and A. D. Riggs. 1986. “Active X Chromosome DNA Is Unmethylated at Eight CCGG Sites Clustered in a Guanine-plus-Cytosine-Rich Island at the 5’ End of the Gene for Phosphoglycerate Kinase.” Molecular and Cellular Biology 6 (11): 4122–25.

Kennard, Malcolm L. 2011. “Engineered Mammalian Chromosomes in Cellular Protein Production: Future Prospects.” Methods in Molecular Biology (Clifton, N.J.). doi:10.1007/978-1-61779-099-7_15.

Lippincott-Schwartz, Jennifer, and Robert D. Phair. 2010. “Lipids and Cholesterol as Regulators of Traffic in the Endomembrane System.” Annual Review of Biophysics 39: 559–78. doi:10.1146/annurev.biophys.093008.131357.

Liu, G., L. Kleine, and R. L. Hébert. 1999. “Advances in the Signal Transduction of Ceramide and Related Sphingolipids.” Critical Reviews in Clinical Laboratory Sciences 36 (6): 511–73. doi:10.1080/10408369991239240.

Marks, Neville, Martin J. Berg, Mariko Saito, and Mitsuo Saito. 2008. “Glucosylceramide Synthase Decrease in Frontal Cortex of Alzheimer Brain Correlates with Abnormal Increase in Endogenous Ceramides: Consequences to Morphology and Viability on Enzyme Suppression in Cultured Primary Neurons.” Brain Research 1191 (January): 136–47. doi:10.1016/j.brainres.2007.10.066.

Marshall, John, Karen M. Ashe, Dinesh Bangari, KerryAnne McEachern, Wei Lien Chuang, Joshua Pacheco, Diane P. Copeland, et al. 2010. “Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease.” PLoS ONE 5 (11): e15033. doi:10.1371/journal.pone.0015033.

Matsuura, Fumito, Masaya Ohta, Yiannis A. Ioannou, and Robert J. Desnick. 1998. “Human α- Galactosidase A: Characterization of the N-Linked Oligosaccharides on the Intracellular and Secreted Glycoforms Overexpressed by Chinese Hamster Ovary Cells.” Glycobiology 8 (4): 329–39. doi:10.1093/glycob/8.4.329.

Mayes, J. S., E. L. Cray, V. A. Dell, J. B. Scheerer, and R. N. Sifers. 1982. “Endocytosis of Lysosomal Alpha-Galactosidase A by Cultured Fibroblasts from Patients with Fabry Disease.” American Journal of Human Genetics 34 (4): 602–10.

Novo, F. J., D. C. Górecki, G. Goldspink, and K. D. MacDermot. 1997. “Gene Transfer and Expression of Human α-Galactosidase from Mouse Muscle in Vitro and in Vivo.” Gene Therapy 4 (5): 488–92. doi:10.1038/

Przybylska, Malgorzata, I. Huan Wu, Hongmei Zhao, Robin J. Ziegler, Jennifer D. Tousignant, Robert J. Desnick, Ronald K. Scheule, Seng H. Cheng, and Nelson S. Yew. 2004. “Partial Correction of the ??-Galactosidase A Deficiency and Reduction of Glycolipid Storage in Fabry Mice Using Synthetic Vectors.” Journal of Gene Medicine 6 (1): 85–92. doi:10.1002/jgm.468.

Puertollano, R., R. C. Aguilar, I. Gorshkova, R. J. Crouch, and J. S. Bonifacino. 2001. “Sorting of Mannose 6-Phosphate Receptors Mediated by the GGAs.” Science (New York, N.Y.) 292 (5522): 1712–16. doi:10.1126/science.1060750.

Stahl, N., H. Jurevics, P. Morell, K. Suzuki, and B. Popko. 1994. “Isolation, Characterization, and Expression of cDNA Clones That Encode Rat UDP-Galactose: Ceramide Galactosyltransferase.” Journal of Neuroscience Research 38 (2): 234–42. doi:10.1002/jnr.490380214.

Strømme, Petter, Jan Eric Månsson, Helge Scott, Kari Skullerud, and Torstein Hovig. 1997. “Encephaloneuropathy with Lysosomal Zebra Bodies and GM2 Ganglioside Storage.” Pediatric Neurology 16 (2). Elsevier: 141–44. doi:10.1016/S0887-8994(96)00298-6.

Van Loo, A., R. Vanholder, K. Madsen, M. Praet, J. Kint, A. De Paepe, L. Messiaen, et al. 1996. “Novel Frameshift Mutation in a Heterozygous Woman with Fabry Disease and End-Stage Renal Failure.” American Journal of Nephrology 16 (4): 352–57.

van Meer, G., and K. Simons. 1988. “Lipid Polarity and Sorting in Epithelial Cells.” Journal of Cellular Biochemistry 36 (1): 51–58. doi:10.1002/jcb.240360106.

Witschel, H., and J. Mathyl. 1969. “Morphological Bases of the Specific Ocular Changes in Fabry’s Disease.” Klinische Monatsblä tter Fü r Augenheilkunde 154 (4): 599–605.

Wraith, J. Edmond, Anna Tylki-Szymanska, Nathalie Guffon, Y. Howard Lien, Michel Tsimaratos, Ashok Vellodi, and Dominique P. Germain. 2008. “Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-Label Study in Pediatric Patients with Fabry Disease.” Journal of Pediatrics 152 (4): 563–70. doi:10.1016/j.jpeds.2007.09.007.

Young, Megan M., Mark Kester, and Hong-Gang Wang. 2013. “Sphingolipids: Regulators of Crosstalk between Apoptosis and Autophagy.” Journal of Lipid Research 54 (1): 5–19. doi:10.1194/jlr.R031278.

Zhu, Y., B. Doray, A. Poussu, V. P. Lehto, and S. Kornfeld. 2001. “Binding of GGA2 to the Lysosomal Enzyme Sorting Motif of the Mannose 6-Phosphate Receptor.” Science (New York, N.Y.) 292 (5522): 1716–18. doi:10.1126/science.1060896.

Ziegler, R. J., N. S. Yew, C. Li, M. Cherry, P. Berthelette, H. Romanczuk, Y. A. Ioannou, K. M. Zeidner, R. J. Desnick, and S. H. Cheng. 1999. “Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer.” Human Gene Therapy 10 (10): 1667–82. doi:10.1089/10430349950017671.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.